Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV‐infected patients in a real‐life cohort from Latin America
Open Access
- 29 March 2017
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 89 (9), 1590-1596
- https://doi.org/10.1002/jmv.24816
Abstract
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real‐clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real‐world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child‐Pugh B at baseline and one patient died due to multi‐organ failure. Follow up HCV‐RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child‐Pugh A cirrhosis in non‐European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child‐Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region.Keywords
This publication has 18 references indexed in Scilit:
- Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER studyAlimentary Pharmacology & Therapeutics, 2016
- Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical PracticeAnnals of Pharmacotherapy, 2016
- Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrenceHepatology, 2016
- Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeksJournal of Hepatology, 2015
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCVThe New England Journal of Medicine, 2014
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with CirrhosisThe New England Journal of Medicine, 2014
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinThe New England Journal of Medicine, 2014
- Trends and projections of hepatitis C virus epidemiology in Latin AmericaLiver International, 2011
- Response to Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis C in Hispanics Compared to Non-Hispanic WhitesThe American Journal of Gastroenterology, 2009
- Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable FactorsGastroenterology, 2008